Tags: treatment + rrms.with.MS

Sort by: Date / Title / URL

1. Early Interferon Beta-1B (BetaseronR) In Multiple Sclerosis Patients Staves Off Disability
   "We have shown for the first time that immediate treatment after a first clinical demyelinating event suggestive of MS can reduce the early neurological damage, which may ultimately delay the development of the debilitating sequelae that characterize adv
   03-05-2007 to drugs, multiple sclerosis, newly diagnosed, relapsing remitting, research, rrms, study, treatment by admin
2. Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
   Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
   17-01-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, research, rrms, treatment by admin
3. Multiple Sclerosis Charity 'Bitterly Disappointed' at Scottish Drugs No
   The MS Society is 'bitterly disappointed' after the Scottish Medicines Consortium (SMC) advised health professionals not to prescribe Tysabri - the only drug licensed for multiple sclerosis (MS) that has shown significant promise in slowing the progress
   12-12-2006 to drugs, multiple sclerosis, relapsing remitting, rrms, treatment, tysabri, uk by admin
4. Avonex Improves Patient Convenience
   AVONEX(R) (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, may now be stored at room temperature (up to 77 degrees F or 25 degrees C) in its prefilled formulation for a period up to 7 days.
   21-10-2006 to avonex, drug company, drugs, interferon, multiple sclerosis, relapsing remitting, rrms, treatment by admin
5. TYSABRI.com
   TYSABRI® is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations.
   07-10-2006 to drug company, drugs, multiple sclerosis, relapsing remitting, rrms, treatment, tysabri by admin
6. Interferon benefits early multiple sclerosis | Science&Health | Reuters.co.uk
   Early and ongoing treatment with interferon beta-1a can provide lasting benefits to patients with relapsing-remitting multiple sclerosis (MS), according to a report in the journal Neurology
   05-10-2006 to avonex, betaseron, drugs, interferon, multiple sclerosis, newly diagnosed, rebif, relapsing remitting, rrms, treatment by admin
7. Teva Says Copaxone Slows Tissue Damage - MSN Money
   Generic drug maker Teva Pharmaceutical Industries Ltd. said Monday new data from a study of its multiple sclerosis drug reinforce previous information that the treatment reduces relapses of symptoms and may slow tissue damage associated with the disease.
   03-10-2006 to copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, relapsing remitting, research, rrms, study, treatment by admin
8. News - Glatiramer Acetate Shows Positive Impact on Average Relapse Rate and Disease Progression in Multiple Sclerosis For Up to 5 Years: Presented at ECTRIMS
   Treatment of relapsing-remitting multiple sclerosis (MS) with glatiramer-acetate (glatiramer, Copaxone) is safe and effective, and it has a positive impact on average relapse rate and disease progression scores.
   01-10-2006 to copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, pregnancy, relapsing remitting, research, rrms, study, treatment by admin
9. Very Active Multiple Sclerosis Patients Benefited from COPAXONE(R) Treatment Following Short-Term Induction with Mitoxantrone. Genetic Engineering News - Biotechnology from Bench to Business
   A new study showed that very active patients who received COPAXONE(R) (glatiramer acetate injection) therapy alone following short-term induction treatment with mitoxantrone experienced an 89 percent greater reduction (Pless than0.0001) compared to those
   30-09-2006 to copaxone, drug company, drugs, mitoxantrone, multiple sclerosis, relapsing remitting, research, rrms, study, treatment by admin
10. PharmaLive: Betaferon Demonstrates Robust Reduction in Risk of Developing Multiple Sclerosis Across All Subgroups of Benefit study
    Schering AG Germany, announced today results from the subgroup analysis of the BENEFIT* study which showed that Betaferon® (interferon beta-1b) 250mcg treatment reduced the risk of developing clinically definite MS (CDMS) consistent
    30-09-2006 to betaseron, drug company, drugs, interferon, multiple sclerosis, newly diagnosed, relapsing remitting, research, rrms, study, treatment by admin
11. Rituxan is effective in relapsing-remitting multiple sclerosis
    The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions observed on serial MRI scans of the brain at weeks 12, 16, 20 and 24 in the Rituxan-treated group compared to placebo
    29-09-2006 to clinical trial, multiple sclerosis, relapsing remitting, research, rituxan, rrms, study, treatment by admin
12. Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status by FDA: Financial News - Yahoo! Finance
    Serono announced today that oral cladribine has been designated a Fast Track product by the US Food and Drug Administration (FDA).
    21-09-2006 to cladribine, drug company, drugs, relapsing remitting, rrms, treatment by admin
13. All Headline News - Oral MS Drug May Be Effective In Treating Multiple Sclerosis - September 14, 2006
    A new study suggests the experimental drug fingolimod may be effective in helping patients with relapsing multiple sclerosis.
    14-09-2006 to drug company, drugs, fingolimod, multiple sclerosis, relapsing remitting, rrms, treatment by admin
14. Teva Initiates Phase III Study To Confirm Increased Efficacy Of Higher Dose Of Glatiramer Acetate For Relapsing-Remitting Multiple Sclerosis
    Teva Pharmaceutical Industries Ltd. announced the initiation of a large Phase III study designed to confirm the positive results from the Phase II study which compared a new higher dose of 40 mg/day dose of glatiramer acetate (GA) to the currently approve
    07-08-2006 to clinical trial, copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, relapsing remitting, research, rrms, study, treatment by admin
15. Cambridge Antibody - ABT-874
    ABT-874 is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.
    30-07-2006 to abt-874, clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, rrms, spms, treatment by admin

First / Previous / Next / Last / Page 1 of 2